Furthermore, when the patient cohort was divided by clinical stages and stratified according to expression of VEGF, in NPC patients with advanced clinical stage (stages III+IV), the 5-year survival rate in NPC patients with VEGF over-expression was significantly lower than that of patients with VEGF low-expression (35.03% vs. 65.22%, respectively; P = 0.0025; Figure 5C); whereas in early stages NPC (stages I+II), the difference was not significant between NPC patients with VEGF over-expression and those with VEGF low-expression (60.46% vs. 73.17%, respectively; P = 0.554; Figure 5B). Here, VEGFA is linked to nasopharyngeal carcinoma.